Parainfluenza Virus Type 3 Overview

Save information for later
Sign Up

Learn About Parainfluenza Virus Type 3

What is the definition of Parainfluenza Virus Type 3?
Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (HPIV) that cause a variety of respiratory illnesses. Symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. Symptoms may include fever, runny nose, and cough. HPIV-3 can also cause bronchiolitis, bronchitis, and pneumonia. Infants and young children are particularly susceptible to HPIV-3 infections, though older adults and those with a weakened immune system are also at risk for complications. HPIVs are usually spread from an infected person to others through coughing, sneezing, and/or touching. Most adults have antibodies against parainfluenza but can get repeat infections.
What are the alternative names for Parainfluenza Virus Type 3?
  • Parainfluenza virus type 3
  • Human parainfluenza virus type 3
  • PIV3
Who are the top Parainfluenza Virus Type 3 Local Doctors?
Dr. Mark H. Gerold
Family Medicine
Dr. Mark H. Gerold
Family Medicine
6402 Route 30, 
Jeannette, PA 
 (1.3 mi)
724-523-5505
Languages Spoken:
English
See accepted insurances

Mark Gerold is a Family Medicine provider in Jeannette, Pennsylvania. Dr. Gerold and is rated as an Experienced provider by MediFind in the treatment of Parainfluenza Virus Type 3. His top areas of expertise are Parainfluenza Virus Type 3, Parainfluenza, Otitis, and Bronchitis.

Dr. Thor C. Mathos
Family Medicine
Dr. Thor C. Mathos
Family Medicine

Excela Health Physician Practices, Inc

8775 Norwin Ave, 
N Huntingdon, PA 
 (4.1 mi)
724-861-6320
Languages Spoken:
English
See accepted insurances

Thor Mathos is a Family Medicine provider in N Huntingdon, Pennsylvania. Dr. Mathos and is rated as an Experienced provider by MediFind in the treatment of Parainfluenza Virus Type 3. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Familial Hypertension, and Glucocorticoid-Remediable Aldosteronism.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Thomas G. Tomci
Internal Medicine
Dr. Thomas G. Tomci
Internal Medicine

Excela Health Physician Practices, Inc

200 Village Dr, 
Greensburg, PA 
 (8.5 mi)
724-689-0520
Languages Spoken:
English
See accepted insurances

Thomas Tomci is an Internal Medicine provider in Greensburg, Pennsylvania. Dr. Tomci and is rated as an Experienced provider by MediFind in the treatment of Parainfluenza Virus Type 3. His top areas of expertise are Familial Hypertriglyceridemia, Hashimoto Thyroiditis, Maturity Onset Diabetes of the Young, and Type 2 Diabetes (T2D).

View All Doctors
What are the latest Parainfluenza Virus Type 3 Clinical Trials?
A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older
A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older
Enrollment Status: Recruiting
Publish Date: October 26, 2024
Intervention Type: Biological
Study Phase: Phase 1

Summary: The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called antibodies (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV va...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vectored Vaccines Expressing the Fusion Glycoprotein of Human Metapneumovirus (HMPV), Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Phase I Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vectored Vaccines Expressing the Fusion Glycoprotein of Human Metapneumovirus (HMPV), Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Enrollment Status: Recruiting
Publish Date: August 12, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 1

Summary: HPIV3 and HMPV are viruses that can cause breathing problems in children. The goal of this clinical trial is to look at the safety of 2 experimental HPIV3/HMPV vaccines in HPIV3-seropositive children ≥ 24 months to \< 60 months of age. Children will receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, or placebo, and participants will not know which study product they have received. T...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center